Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK ‐rearranged lung cancer-Reference-Cited by-同舟云学术

Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK ‐rearranged lung cancer

Published:2019-10-21 Issue:12 Volume:11 Page:
ISSN:1757-4676
Container-title:EMBO Molecular Medicine
language:en
Short-container-title:EMBO Mol Med

Author:

Yun Mi Ran¹²^ORCID,Choi Hun Mi²,Lee You Won²,Joo Hyeong Seok¹,Park Chae Won²,Choi Jae Woo³⁴,Kim Dong Hwi¹,Kang Han Na¹²,Pyo Kyoung‐Ho²,Shin Eun Joo²,Shim Hyo Sup⁵,Soo Ross A⁶,Yang James Chih‐Hsin⁷⁸,Lee Sung Sook⁹,Chang Hyun¹⁰,Kim Min Hwan²,Hong Min Hee²,Kim Hye Ryun²,Cho Byoung Chul²^ORCID

Affiliation:

1. JEUK Institute for Cancer Research JEUK Co., Ltd. Gumi‐City Korea

2. Division of Medical Oncology Yonsei Cancer Center Yonsei University College of Medicine Seoul Korea

3. Department of Pharmacology Yonsei University College of Medicine Seoul Korea

4. Severance Biomedical Science Institute Yonsei University College of Medicine Seoul Korea

5. Department of Pathology Yonsei University College of Medicine Seoul Korea

6. Department of Haematology‐Oncology National University Cancer Institute Singapore Singapore

7. Graduate Institute of Oncology National Taiwan University Taipei Taiwan

8. Department of Oncology National Taiwan University Hospital Taipei Taiwan

9. Department of Hematology‐Oncology Inje University Haeundae Paik Hospital Busan Korea

10. International St. Mary's Hospital College of Medicine Catholic Kwandong University Incheon Korea

Funder

National Research Foundation of Korea

Publisher

EMBO

Subject

Molecular Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.15252/emmm.201910581

Reference56 articles.

1. ALK inhibitors in non‐small cell lung cancer: crizotinib and beyond;Awad MM;Clin Adv Hematol Oncol,2014

2. Photosensitizers and Photodynamic Therapy: Verteporfin

3. Photodynamic therapy with verteporfin (Visudyne): impact on ophthalmology and visual sciences;Bressler NM;Invest Ophthalmol Vis Sci,2000

4. The clinically used photosensitizer Verteporfin (VP) inhibits YAP-TEAD and human retinoblastoma cell growth in vitro without light activation

5. Functional genomics screen identifies YAP1 as a key determinant to enhance treatment sensitivity in lung cancer cells

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Induction of resistance to neurotrophic tropomyosin‐receptor kinase inhibitors by HMGCS2 via a mevalonate pathway;Cancer Medicine;2024-06

2. Energy metabolism as the hub of advanced non-small cell lung cancer management: a comprehensive view in the framework of predictive, preventive, and personalized medicine;EPMA Journal;2024-04-08

3. Hippo pathway in non-small cell lung cancer: mechanisms, potential targets, and biomarkers;Cancer Gene Therapy;2024-03-18

4. Deterministic reprogramming and signaling activation following targeted therapy in non-small cell lung cancer driven by mutations or oncogenic fusions;Expert Opinion on Investigational Drugs;2024-02-23

5. Role Of YAP Signaling in Regulation of Programmed Cell Death and Drug Resistance in Cancer;International Journal of Biological Sciences;2024